v3.26.1
Shareholders’ equity
 6 Months Ended
Jun. 30, 2026
Stockholders' Equity Note [Abstract]  
Shareholders’ equity Shareholders’ equity
Authorized share capital
The Company’s authorized share capital consists of an unlimited number of common shares and preferred shares, without par value, and 1,164,000 Series A participating convertible preferred shares, without par value.
Open Market Sale Agreement

Effective March 26, 2025, the Company terminated its Open Market Sale Agreement with Jefferies LLC dated December 20, 2018, as amended (the Sale Agreement), under which the Company could issue and sell common shares, from time to time.

The Company did not issue any common shares pursuant to the Sale Agreement during the six months ended June 30, 2026 or 2025.
Stock-based compensation

The table below summarizes information about the Company’s stock-based compensation for the three and six months ended June 30, 2026 and 2025 and the expense recognized in the condensed consolidated statements of operations:
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Stock options
Options granted during period385,800 762,400 1,338,200 4,706,122 
Weighted average exercise price$4.32 $3.34 $4.37 $3.32 
Restricted stock units (RSUs)
Restricted stock units granted during period— — 371,500 901,900 
Grant date fair value$— $— $4.39 $3.29 
Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
(in thousands)(in thousands)
Stock compensation expense
Research and development$271 $374 $687 $929 
General and administrative1,324 390 2,230 1,128 
Total stock compensation expense$1,595 $764 $2,917 $2,057